The device is designed for highly accurate and reliable long-term continuous remote monitoring of patients with atrial fibrillation, syncope and bradycardia.
Biotronik, a leading manufacturer of cardio- and endovascular medical technology, has received CE approval for its BioMonitor 2 implantable continuous wireless cardiac monitor. According to the company, the results of a pilot study into the performance of BioMnitor 2 show the reliability of the unique, subcutaneous, insertable cardiac monitor.
The study demonstrated that monitor can provide an insertion time of less than two minutes, high R-Wave amplitudes and a greater than 90% success rate for daily biotronik home monitoring transmissions.
Also, the device has a capacity of over 60 minutes of ECG recording time and can transmit up to six subcutaneous ECG daily via Home Monitoring.
“The results of the BioMonitor 2 study confirm the deliverability of the device and the excellent sensing amplitudes afforded by the increased sensing vector length.
I am hopeful that future trials will show that this translates into improved diagnostic abilities that will aid physicians in the treatment of their patients,” said Dr. Sze-Yuan Ooi, Prince of Wales Hospital, Sydney, Australia.
The device is designed for highly accurate and reliable long-term continuous remote monitoring of patients with atrial fibrillation, syncope, bradycardia and tachycardia.
Advertisement
Advertisement